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o I adjudicate events in clinical trials sponsored by 
Merck and I serve on the DSMB for a clinical study 
funded by Medtronic.  I am a consultant to Pierre 
Fabre (France)  
 
o I receive grant support from NINDS and St Jude 
Medical  
 
o I will discuss therapies for treatment of stroke that 
are not approved by the FDA  
o Advances in the diagnosis, prevention and 
treatment of stroke continue to occur 
o Resulting in changes in patient 
o These changes are reflected in national 
guidelines  
o These changes also are generating questions 
by clinicians  
o Time to address some of these questions 
o Try to answer 7 of these question   
o What should our blood pressure 
targets be now in the management 
of patients with acute ischemic or 
hemorrhagic stroke?  
o Arterial hypertension is commonly detected in the 
setting of an acute ischemic or hemorrhagic stroke 
o Arterial hypertension is a premier risk factor for 
premature atherosclerosis and both ischemic and 
hemorrhagic stroke 
o An elevated blood pressure may be a consequence 
of the stroke 
o Stress of the acute event (headache, agitation, nausea, 
vomiting, white coats, etc.) 
o Compensatory measure to maintain cerebral blood flow 
in setting of ischemia or increased intracranial pressure 
o Adverse impact of hypertension  
o Potentiate bleeding or recurrent rupture of aneurysm 
o Hemorrhagic transformation of infarction 
o Potential adverse effects  of rapid lowering of 
blood pressure 
o Loss of autoregulation leads to pressure-dependent 
blood flow 
o Lowering blood pressure may worsen ischemia distal to 
an arterial occlusion 
o Lowering blood pressure may worsen ischemia in a 
patient with increased intracranial pressure  
o Spontaneous decline in blood pressure during first 
24 hours 
o Erratic responses to medications 
o Uncertainties in medical management 
o Level of blood pressure that mandates treatment 
o Desired decline in blood pressure 
o Selection of acutely administered medications  
o Transitioning to longer term care with restarting or 
adjusting antihypertensive medications  
o Clinical trials have given inconclusive results 
o Randomized trial – 4071 patients 
o No thrombolysis and treated < 48 hours 
o Goal of reducing blood pressure 10% - 25% in 24 
hours and goal of < 140/90 mm Hg 
o Outcomes at 14 days/discharge and 3 months  
o Death/disability (mRS > 3) 
o Did lower blood pressures – 24 hours 
o Treatment:  mean systolic pressure reduced 12.7% 
o Control: mean systolic pressure reduced 7.2% 
o Outcomes 
o No significant differences between groups 
   He et al, JAMA; 2013 (online)  
o If systolic BP >200 mm Hg or MAP > 150 mm Hg 
o Aggressive lowering with continuous IV infusion and 
measurements of blood pressure every 5 minutes 
o If systolic BP > 180 mm Hg or MAP > 130 mm Hg and 
there is concern about increased ICP  
o Monitor ICP and reducing BP carefully with intermittent or 
continuous IV infusion – maintain CPP > 60 mm Hg  
o If systolic BP > 180 mm Hg or MAP > 130 mm Hg and 
there is no evidence of increased ICP 
o Modest reduction of blood pressure to MAP 110 Hg or target 
value of 160/90 – intermittent/continuous meds 
   Morgenstern et al, Stroke; 2010; 41: 2108   
o Intravenous administration of 
o Labetalol 
o Bolus: 5-20 mg every 15 minutes 
o Infusion: 2mg/min (maximum 300 mg/day) 
o Hydralazine 
o Bolus:5 – 20 mg every 30 minutes 
o Infusion: 1.5 – 5 µg/kg/minute 
o Nicardipine 
o Infusion: 5 – 15 mg/hour 
o Indications 
o Mean arterial pressure> 120 mm Hg 
o Systolic blood pressure > 160 mm Hg 
o Diastolic blood pressure > 100 mm Hg 
o Maintain cerebral perfusion pressure > 60 mm Hg 
o Blood pressure < 185 mm Hg systolic AND 110 mm 
Hg diastolic to administer rtPA 
o Aggressive treatment to achieve blood pressure 
o Keep below these levels after treatment  
o In other circumstances, goal is to lower blood 
pressure by approximately 15% in first 24 hours 
o No solid data, general consensus 
o Treat if blood pressure > 220 mm Hg systolic or 120 mm 
Hg diastolic 
  Jauch et al, Stroke, 2013  
o Short acting medications given intravenously 
o Can be stopped if blood pressure drops too much or if the 
patient worsens neurologically   
o Choices 
o Labetalol 10 – 20 mg over 1 – 2 min, repeat x 1 
o Nicardipine 5 mg/hr infusion, may increase by 2.5 mg/hr 
q 5 – 15 min, maximum 15 mg/hr 
o Requires continuous blood pressure monitoring  
o Can try hydralazine, enalaprilat, sodium nitroprusside 
o If sodium nitroprusside is required, patient generally can not 
receive tPA  
 Jauch et al, Stroke, 2013  
 
o What is the upper time limit for 
treatment with rtPA to be 
effective? 
o What is the upper age limit for 
thrombolytic therapy  
Favorable outcomes 
 rt-PA   Control Odds Ratio p-value 
 
Treated < 6 hr 
   1609/3482     1434/3403        1.18 (1.07-1.30) p =0.001 
Treated < 3 hr 
    365/896      280/883        1.56 (1.28-1.90) p <0.0001 
Treated 3 – 6 hr 
   1180/2490     1133/2481        1.07 (0.96-1.21) p = 0.23 
 
   Wardlaw et al, Lancet, 2012 
 Pooled analyses of clinical trials  
 
 Time  Odds of Favorable Outcomes 
 < 90 minutes  2.55  (1.44 – 4.52) 
 91 – 180 minutes 1.64 (1.12 – 2.40) 
 180 – 270 minutes 1.34  (1.06 – 1.68) 
 270 – 360 minutes 1.22 (0.92 – 1.61) 
   Lees et al, Lancet, 2010; 375: 1695 
o European trial demonstrated efficacy out to 4.5 
hours – time period included in current guidelines 
o Not as effective as earlier treatment 
o Not likely to expand time window much more 
o Are some differences in selection criteria from 
treatment < 3 hours 
o Exclusions for 3 – 4.5 hours  
o Age > 80 
o History of diabetes and prior (clinical) stroke 
o NIH Stroke Scale score > 25 
o Use of oral anticoagulants regardless of INR  
 




o Age restriction for treatment of persons 3 – 4.5 
hours 
o Do not treat persons older than 80  
o Do carotid Dopplers add anything if 
we have the results of a MRA of the 
head/neck? 
o CTA 
o Extracranial/intracranial vessels – at time of CT 
o Involves IV contrast – contrast nephrotoxicity 
o Availability of 3-D reconstruction of images  
o MRA 
o Extracranial/intracranial vessels – at time of MRI 
o Involves IV contrast – contraindicated in renal failure 
o Pacemaker, claustrophobia, metal  
o May over-estimate degree of arterial narrowing  
o Carotid duplex (Doppler)  
o Visualizes carotid bifurcation only 
o Provides information about the arterial wall 
o Subject to performance variability 
o MRA and CTA are more expensive that carotid 
duplex  
o Advantage of imaging both intracranial and extracranial 
vasculature  
o Do not image smaller intracranial vessels  
o Detect aneurysms, vascular malformations  
o Some surgeons want confirmation about the 
nature of the arterial lesion before deciding about 
carotid endarterectomy 
o Generally, a carotid duplex is not needed if carotid 
endarterectomy is not planned  
 
 
o Is transthoracic echocardiography 
sufficient to look for clot?  
o Accounts for approximately 20% - 25% of ischemic 
strokes 
o Occurs in persons of all ages regardless of sex or 
ethnicity 
o Causes vary by age 
o Congenital heart disease in children 
o Atherosclerotic heart disease in older persons 
o Some patients may not have overt cardiac 
symptoms or signs 
o Non-invasive 
o Limited sensitivity 
o Large chest or obese 
o Images left ventricle – wall, chamber 
o Ventricular aneurysm 
o Ventricular akinesia 
o Intraventricular thrombus or mass 
o Also may detect atrial myxoma, PFO, valvular 
lesions  
o Minimally invasive 
o Esophageal disease 
o Risk of bleeding or aspiration 
o Requires sedation and analgesia 
o Images  
o Left atrium and appendage 
o Valves 
o Aorta 
o More sensitive than TTE 
o Detects lesions of uncertain significance 
 
o Enlargement of left atrium or appendage 
o Thrombus in left atrium or appendage 
o Inter-atrial septal lesions 
o Atrial turbulence (“smoke”) 
o Valvular lesions 
o Vegetation 
o Lambl excresence 
o Calcification 
o Valvular strands 
o Atherosclerotic disease of the aorta 
o Intravenously administer agitated saline 
o Assess movement of bubbles 
o Right and left sides of the heart 
o Early appearance on the left side 
o Right-to-left shunt 
o Found with  
o Atrial or ventricular septal defect 
o Patent foramen ovale 
o Pulmonary arteriovenous malformation 
o Cardiac imaging remains important in evaluation 
of patients with ischemic stroke 
o Can be avoided if other cause established  
o Cardiogenic embolism usually arises from lesions in 
the left atrium, left atrial appendage, mitral valve 
o Indications for TTE 
o Presumed left ventricular origin  
o Anterior wall MI, ventricular aneurysm 
o Indications for TEE 
o To search most other possible cardiac causes of stroke  
 
 
o What is the role of statins in 
management of acute stroke? 
o Increasing evidence that hyperlipidemia is a risk 
factor for ischemic stroke 
o Promotes large artery atherosclerosis and small vessel 
brain disease 
o Also indirectly leads to stroke via cardioembolism in 
patients with coronary artery disease  
o Measuring levels of cholesterol in a patient with 
stroke is a quality measure 
o Now done in virtually all patients with ischemic stroke   
o Inhibit HMG-CoA reductase, the rate-limiting enzyme of 
the mevalonate pathway for cholesterol synthesis 
o Also increased clearance of LDL lipoprotein from the blood 
o Modest increase in HDL cholesterol levels 
o Reduce triglycerides by 20% - 40% 
o Majority of cholesterol synthesis is at night – rationale 
for giving medication in the evening 
o Improve endothelial function and maintain plaque 
stability 
o Modulate inflammatory responses 
o Prevent formation of thrombi  
  Atorvastatin  Placebo p-value 
  (80 mg/d) 
  N = 2365  N= 2366 
Fatal or non- 
fatal stroke 265 11.2%  311 13.1% 0.05 
TIA  153 6.5%  206 8.8% 0.004 
Coronary 
event  81 3.4%  121 5.1% 0.006 
Death  216 9.1%  211 8.9% 0.77 
ICH  55   33 
 
   SPARCL , N Engl J Med, 2006; 355: 549 
o Most powerful medications to lower LDL cholesterol 
o First choice for treatment of most patients with ischemic 
stroke  
o Choice of medication 
o Rosuvastatin, atorvastatin, and simvastatin have the greatest 
impact on lowering LDL cholesterol 
o Atorvastatin and fluvastatin do not require dose adjustment in 
patients with renal disease 
o Lower doses of pravastatin or rosuvastatin in patients with liver 
disease 
o Pravastatin and fluvastatin are the least likely to cause muscle 
toxicity  
o May be some increase in risk of hemorrhagic stroke 
with aggressive lowering of LDL cholesterol 
o May wish to avoid medications in this situation  
o Muscle disease  
o Relatively uncommon with treatment with statin alone 
o Myalgias: 2% - 11%, myositis: 0.5%, myoglobinuria: 0.1% 
o Usually begins within the first weeks of treatment 
o Monitored by CK levels  
o Variation of SLCO1B1 gene, which is involved in the 
absorption of statins, increases risk 
o Increased risk if renal dysfunction 
o Increased risk with medications that block CYP3A4 
 
o Is there a role for SSRIs in acute 
stroke?   
o Approximately 75% persons with stroke survive 
and need some rehabilitation (400,000 
annually) 
o Measures to maximize recovery could be 
prescribed to large numbers of patients  
o No medical treatment has been established as 
effective – given as an adjunct to current 
rehabilitation  
o Potential for a much larger impact on the 
public’s health than time-limited acute 
treatments  
 
o Changes in metabolic activity in both the 
ipsilateral and contralateral cerebral 
hemispheres 
o First hours and days 
o Changes in CBF and CMRO2 
o Edema, diaschisis, inflammation 
o First days and weeks 
o Cellular growth and excitability 
o Structural and physiological changes 
o First weeks and months 
o Treatment and experience effects 
    Cramer, Stroke, 2004; 36: 2695 
 
o Common consequence of stroke  
o Associated with impaired recovery 
o Motor performance 
o Cognitive recovery 
o Activities of daily living 
o Associated with increased mortality 
o Effects persist event when adjusting for age, 
severity of impairments, and comorbid illnesses  
 
o SSRI increase expression of VEGF in the dentate 
gyrus of the hippocampus in experimental models 
o The effects of SSRI may be augmented because of 
increases in VEGF 
o SSRI may improve both motor and sensory deficits 
after stroke  
o Thus, SSRI may be superior to other classes of 
antidepressants to improve outcomes after stroke 
 Gallard and Mir, Lancet Neurology, 2011; 10: 499  
 
o Randomized trial in 8 French centers testing 
fluoxetine 20 mg/day for 3 months in addition to 
rehabilitation 
o Fluoxetine – 57 subjects, placebo – 56 subjects 
o Outcomes assessed at 3 months by Fugl-Myer and 
mRS scores 
  Fluoxetine    Placebo            P-value 
   Fugl-Myer      53.7 +/- 27.8   35.1 +/- 22 0.0006  
    FM Improve  36.4 +/- 21.3   21.9 +/- 16.7      0.003 
    mRS 0 – 2     15 (26%)        5 (9%)  0.015 
   Chollet et al, Lancet Neurology, 2011; 10: 123 
o Have tried to answer some of the more common 
questions about stroke care 
o The management of hypertension in the setting of 
acute stroke remains unsettled 
o Still, recommendations about situations to lower BP 
o Caution should be exercised in lowering the BP  
o The time window for treatment with intravenous 
thrombolysis has expanded to 4.5 hours 
o Generally the same criteria as for treatment < 3 hours 




o Examination of the vasculature and heart remain 
important components of the assessment for the cause 
of ischemic stroke 
o Carotid duplex ultrasonography is an option but its 
limitations should be recognized 
o In general, TEE provides more information about the 
cause of stroke than does TTE 
o TTE does have some role in evaluation 
o Treatment of hyperlipidemia is an important part of 
long-term care of persons with ischemic stroke 
o The use of SSRI may help augment recovery after 
stroke  
